A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer
An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer
Sponsor: Sanofi
A PHASE2 clinical study on Operable T2-3N+M0 Rectal Cancer (Stage III), this trial is completed. The trial is conducted by Sanofi and has accumulated 14 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2021 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
- Sir Mortimer B. Davis - Jewish General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .